美国退伍军人中精神分裂症、双相障碍和抑郁症多基因风险评分的外显率与多效性
该研究基于百万退伍军人计划约40万参与者,评估精神分裂症、双相障碍和抑郁症多基因风险评分(PRS)在退伍军人健康管理系统中的外显率,并探索PRS与1650种疾病类别的关联。欧洲血统者中PRS与精神分裂症(OR 1.81)和双相障碍(OR 1.42)诊断稳健关联,非洲血统者效应量较小。
要点
- 欧洲血统者精神分裂症PRS的OR为1.81,双相障碍PRS的OR为1.42。
- 非洲血统者对应OR较小:精神分裂症1.35,双相障碍1.16。
- 神经精神PRS与多种精神和躯体健康问题风险增加相关。
核心结论
- 基于电子健康记录的表型分析方法在美国退伍军人中有效,PRS有助于区分生物学多效性和中介多效性。
研究设计与样本
- 评估退伍军人健康管理局1999年10月至2021年1月电子健康记录,嵌入9378例确诊精神分裂症或双相I型障碍的队列。
- 在百万退伍军人计划约40万个体中比较精神分裂症、双相障碍和抑郁症PRS在非洲或欧洲血统参与者中的表现。
- 探索PRS与基于ICD-9/10计费代码的1650种疾病类别的关联。
- 应用基因组结构方程模型推导索引共同和疾病特异性遗传因子的新型PRS。
主要发现
- 9378例确诊精神分裂症或双相I型障碍个体中,8962例(95.6%)通过ICD-9/10代码(2次或以上)正确识别。
- 欧洲血统者中PRS与精神分裂症诊断稳健关联(OR 1.81,95%CI 1.76-1.87,P<10^-257)。
- 欧洲血统者中PRS与双相障碍诊断稳健关联(OR 1.42,95%CI 1.39-1.44,P<10^-295)。
- 非洲血统者中精神分裂症PRS效应量较小(OR 1.35,95%CI 1.29-1.42,P<10^-38)。
- 非洲血统者中双相障碍PRS效应量较小(OR 1.16,95%CI 1.11-1.12,P<10^-10)。
关键数值与推荐
- PRS与精神分裂症和双相障碍诊断的关联以OR和95%CI报告,按血统分层。
- 电子健康记录表型定义使用ICD-9/10计费代码(2次或以上)与面对面结构化临床访谈确诊比较。
临床怎么用
- 在退伍军人健康管理系统中,基于电子健康记录的表型定义可有效识别精神分裂症或双相I型障碍病例。
- PRS可用于探索精神疾病与躯体疾病之间的遗传多效性关联,但需注意血统间效应量差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Serious mental illnesses, including schizophrenia, bipolar disorder, and depression, are heritable, highly multifactorial disorders and major causes of disability worldwide. OBJECTIVE: To benchmark the penetrance of current neuropsychiatric polygenic risk scores (PRSs) in the Veterans Health Administration health care system and to explore associations between PRS and broad categories of human disease via phenome-wide association studies. DESIGN, SETTING, AND PARTICIPANTS: Extensive Veterans Health Administration's electronic health records were assessed from October 1999 to January 2021, and an embedded cohort of 9378 individuals with confirmed diagnoses of schizophrenia or bipolar 1 disorder were found. The performance of schizophrenia, bipolar disorder, and major depression PRSs were compared in participants of African or European ancestry in the Million Veteran Program (approximately 400 000 individuals), and associations between PRSs and 1650 disease categories based on ICD-9/10 billing codes were explored. Last, genomic structural equation modeling was applied to derive novel PRSs indexing common and disorder-specific genetic factors. Analysis took place from January 2021 to January 2022. MAIN OUTCOMES AND MEASURES: Diagnoses based on in-person structured clinical interviews were compared with ICD-9/10 billing codes. PRSs were constructed using summary statistics from genome-wide association studies of schizophrenia, bipolar disorder, and major depression. RESULTS: Of 707 299 enrolled study participants, 459 667 were genotyped at the time of writing; 84 806 were of broadly African ancestry (mean [SD] age, 58 [12.1] years) and 314 909 were of broadly European ancestry (mean [SD] age, 66.4 [13.5] years). Among 9378 individuals with confirmed diagnoses of schizophrenia or bipolar 1 disorder, 8962 (95.6%) were correctly identified using ICD-9/10 codes (2 or more). Among those of European ancestry, PRSs were robustly associated with having received a diagnosis of schizophrenia (odds ratio [OR], 1.81 [95% CI, 1.76-1.87]; P < 10-257) or bipolar disorder (OR, 1.42 [95% CI, 1.39-1.44]; P < 10-295). Corresponding effect sizes in participants of African ancestry were considerably smaller for schizophrenia (OR, 1.35 [95% CI, 1.29-1.42]; P < 10-38) and bipolar disorder (OR, 1.16 [95% CI, 1.11-1.12]; P < 10-10). Neuropsychiatric PRSs were associated with increased risk for a range of psychiatric and physical health problems. CONCLUSIONS AND RELEVANCE: Using diagnoses confirmed by in-person structured clinical interviews and current neuropsychiatric PRSs, the validity of an electronic health records-based phenotyping approach in US veterans was demonstrated, highlighting the potential of PRSs for disentangling biological and mediated pleiotropy.
引用
- Bigdeli TB, Voloudakis G, Barr PB, et al. Penetrance and Pleiotropy of Polygenic Risk Scores for Schizophrenia, Bipolar Disorder, and Depression Among Adults in the US Veterans Affairs Health Care System. JAMA Psychiatry. 2022. PMID: 36103194. doi:10.1001/jamapsychiatry.2022.2742
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。